Abstract: Provided are a communication network switching apparatus, a communication network switching system, and a communication network switching method. The apparatus includes a first communication network interface, a second communication network interface, a processor, a communication network switch, and a device access interface. The communication network switch is configured to switch, according to the control signal of the processor, the connection manner with the first communication network interface and the second communication network interface and connect the first communication network or the second communication network to the processor. The processor is connected to the device access interface and is configured to connect a target communication network connected through the communication network switch to a target device connected to the device access interface.

Abstract: The present invention provides novel compositions and methods based on the discovery of the mechanisms and gene expression programs associated with homeostatic ILC2s and proinflammatory ILC2s that drive tissue inflammation. Immune signaling abnormalities in the small intestine can trigger chronic type 2 inflammation. Applicants analyzed 58,067 immune cells from the mouse small intestine by single-cell RNA-seq at steady state and after induction of a type 2 inflammatory reaction to ovalbumin. Cell type composition and cell programs shifted in response to inflammation, especially in ILC2s. A key transcript in the inflammation-induced program in intestinal KLRG1+ILC2s was exon 5 of Calca, encoding the alpha-calcitonin gene-related peptide (a-CGRP). a-CGRP antagonized IL-25-induced activation of intestinal ILC2s and reduced their frequency in an ovalbumin reaction model. ?-CGRP activated a cAMP response, which suppressed ILC2 proliferation.

Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of tacrolimus and a liquid vehicle comprising at least one semifluorinated alkane for use in a method of treating an intraocular inflammatory eye disease.

Abstract: The present invention relates to a pharmaceutical composition comprising tacrolimus and a semifluorinated alkane for use in the treatment of ocular neovascularisation.

Abstract: The present invention provides novel compositions and methods based on the discovery of the mechanisms and gene expression programs associated with homeostatic ILC2s and proinflammatory ILC2s that drive tissue inflammation. Molecular cues were identified that modulate ILC responses to alarmins using single-cell RNA-sequencing (scRNA-seq) profiles of lung-resident ILCs at steady state and after in vivo stimulation. The neuropeptide CGRP and the CGRP receptor were identified as expressed on ILC2s. Treatment with CGRP reduces allergic lung inflammation and reduces the proliferation and expansion of ILC2 cells. The results demonstrate that CGRP signaling strongly modulates ILC2 responses and highlights the importance of neuro-immune crosstalk in allergic inflammatory responses at mucosal surfaces.

Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of tacrolimus and a liquid vehicle comprising at least one semifluorinated alkane for use in a method of treating an intraocular inflammatory eye disease.

Abstract: An IL-12 production inhibitor which comprises, as an active ingredient, a keratan sulfate oligosaccharide or a derivative thereof, for example, a keratan sulfate oligosaccharide comprising at least one repeating unit of either one of the disaccharides represented by the following formulas: Gal (6s)-GlcNAc (6s) and Gal (6s)-GlcNAc wherein Gal represents a galactose residue, GlcNAc represents an N-acetylglucosamine residue, 6s indicates that 6-0-sulfate ester is formed at a Hydroxyl group at the 6-position, and - represents a glycosidic linkage.